Semaphorin 3A: A potential target for prevention and treatment of nickel allergy

被引:7
|
作者
Liu, Lipei [1 ]
Watanabe, Megumi [1 ]
Minami, Norikazu [1 ]
Yunizar, Mohammad Fadyl [1 ]
Ichikawa, Tetsuo [1 ]
机构
[1] Tokushima Univ, Grad Sch Biomed Sci, Dept Prosthodont & Oral Rehabil, 3-18-15 Kuramoto, Tokushima 7708504, Japan
关键词
NERVE GROWTH-FACTOR; DENDRITIC CELLS; TNF-ALPHA; SCRATCHING BEHAVIOR; SKIN INFLAMMATION; GENE-EXPRESSION; NC/NGA MICE; ACTIVATION; RECEPTORS; KERATINOCYTES;
D O I
10.1038/s42003-022-03641-0
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Metal allergy is one of the typical immune disorders encountered during the application of dental/medical materials and has a highly complex pathogenic mechanism. Semaphorin 3A (Sema3A), a member of the semaphorin family, is reported to be involved in various immune disorders. However, its role in metal allergy has not been clarified yet. Herein, we show that Sema3A expression was upregulated in nickel (Ni) allergy-induced mouse ear tissue and in NiCl2-stimulated mouse keratinocytes. Moreover, Sema3A regulated tumor necrosis factor-alpha production and mitogen-activated protein kinase activation in keratinocytes. The specific deletion of Sema3A in keratinocytes did not affect immune cell infiltration but reduced edema and ear swelling; it also impeded Th1 responses to cause a slight alleviation in Ni allergy in mice. Our results demonstrate that Sema3A promotes the development of metal allergy and should be explored as a potential target for the prevention and treatment of metal allergy. Semaphorin 3A is upregulated in keratinocytes upon nickel exposure, subsequently promoting Th1 cytokine responses and driving nickel allergic reactions.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] The effects of semaphorin 3A in bone and cartilage metabolism: fundamental mechanism and clinical potential
    Wu, Kaile
    Huang, Donghua
    Huang, Xin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
  • [22] Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus
    Vadasz, Zahava
    Haj, Tharwat
    Halasz, Katalin
    Rosner, Itzhak
    Slobodin, Gleb
    Attias, Dina
    Kessel, Aharon
    Kessler, Ofra
    Neufeld, Gera
    Toubi, Elias
    ARTHRITIS RESEARCH & THERAPY, 2012, 14 (03)
  • [23] Semaphorin 3A is a marker for disease activity and a potential immunoregulator in systemic lupus erythematosus
    Zahava Vadasz
    Tharwat Haj
    Katalin Halasz
    Itzhak Rosner
    Gleb Slobodin
    Dina Attias
    Aharon Kessel
    Ofra Kessler
    Gera Neufeld
    Elias Toubi
    Arthritis Research & Therapy, 14
  • [24] Semaphorin 3A: a key player in regulating asthma
    Vadasz, Z.
    Toubi, E.
    ALLERGY, 2014, 69 : 98 - 98
  • [25] Semaphorin 3A is a chemoattractant for cortical apical dendrites
    Franck Polleux
    Theresa Morrow
    Anirvan Ghosh
    Nature, 2000, 404 : 567 - 573
  • [26] SOLUBLE SEMAPHORIN 3A REGULATES THE IMMUNE RESPONSE
    Schlahsa, Laura
    Zenk, Jana
    Aufderbeck, Susanne
    Figueiredo, Constanca
    Blasczyk, Rainer
    HUMAN IMMUNOLOGY, 2009, 70 : S157 - S157
  • [27] Semaphorin 3A Expression in the Colon of Hirschsprung Disease
    Wang, Li-Li
    Fan, Yang
    Zhou, Feng-hua
    Li, Hui
    Zhang, Yi
    Miao, Jia-Ning
    Gu, Hui
    Huang, Tian-Chu
    Yuan, Zheng-Wei
    BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2011, 91 (09) : 842 - 847
  • [28] Inhibition of CNS Remyelination by the Presence of Semaphorin 3A
    Syed, Yasir A.
    Hand, Elisabeth
    Moebius, Wiebke
    Zhao, Chao
    Hofer, Matthias
    Nave, Klaus A.
    Kotter, Mark R.
    JOURNAL OF NEUROSCIENCE, 2011, 31 (10): : 3719 - 3728
  • [29] SEMAPHORIN 3A AS A POSSIBLE IMMUNOREGULATOR IN SYSTEMIC SCLEROSIS
    Rimar, D.
    Rosner, I.
    Slobodin, G.
    Rozenbaum, M.
    Halasz, K.
    Haj, T.
    Jiries, N.
    Kaly, L.
    Boulman, N.
    Daood, R.
    Vadas, Z.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : S66 - S66
  • [30] Overexpression of semaphorin 3A in patients with urothelial cancer
    Vadasz, Zahava
    Rubinstein, Jacob
    Bejar, Jacob
    Sheffer, Huila
    Halachmi, Sarel
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2018, 36 (04) : 161.e1 - 161.e6